Search clinical trials for: Trivalent inactivated influenza virus vaccine (TIV)

Total 30407 results

Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 3, 2011

Influenza
Immune Targeting Systems Ltd

Completed

Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults

Influenza A
Novartis Vaccines

Completed

Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age

Seasonal Influenza

Colombia, Mexico, Panama, Philippines
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
SK Chemicals Co., Ltd.

Completed

Immunogenicity and Safety of Quadrivalent Influenza Vaccine in Children Aged 6~35 Months

Influenza, Human

Korea, Republic of
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

TIV and High Dose TIV in Subjects With Rheumatoid Arthritis

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi Pasteur, TIV + H1N1, Pediatric Population

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Eldery High Dose TIV 2005

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Sanofi H1N1 + TIV - Adults and Elderly

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010

Influenza
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety,Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus Vaccine, Trivalent, Inactivated (TIV) in Children

Respiratory Tract Infections

Spain, Israel
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years

Influenza

United States
BiondVax Pharmaceuticals ltd.

Completed

A Study to Assess the Safety and Immunogenicity of M-001 Influenza Vaccine as a Primer to TIV in Elderly Volunteers

Healthy | Influenza

Israel
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, in Healthy Adults Aged 18 Years and Above

Human Influenza

Belgium
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Influenza Vaccine, Northern Hemisphere Formulation 2013/2014, Including MF59C.1 Adjuvant, in Healthy Adults ≥65 Years of Age

Human Influenza

Belgium
Sanofi

Completed

Immunogenicity and Safety of the Shenzhen Trivalent Inactivated Influenza Vaccine Versus a Trivalent Influenza Vaccine Comparator in Chinese Subjects 18 to 59 Years

Influenza | Flu

China
BiondVax Pharmaceuticals ltd.

Completed

Further Investigation of an Intramuscular Influenza Vaccine (Multimeric-001)

Influenza

Israel
University of Oxford

Completed

A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

A Phase I Safety and Immunogenicity Study of Mix and Match of Licensed Flu Vaccine and Flumist

Influenza

United States
Seqirus

Completed

A Study to Evaluate the Immunogenicity and Safety of bioCSL Quadrivalent Influenza Vaccine (QIV) in Adults Aged 18 Years and Above.

Influenza, Human

United States
MedImmune LLC

Completed

A Phase 2 Study to Evaluate Immune Responses of FluMist®

Influenza Vaccine

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)

Influenza

United States
PATH
Centers for Disease Control and Prevention; Institut Pasteur; Institut de Recherche...

Completed

Inactivated Influenza Vaccine Effectiveness in Tropical Africa

Influenza

Senegal
MedImmune LLC

Completed

Study to Evaluate the Immune Responses of Trivalent Cold-Adapted Influenza Vaccine (CAIV-T) Compared With (TIV)

Influenza

United States
University of Oxford

Completed

ADITEC FLU STUDY: Understanding the Genetic Basis for Immune Responses

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women

Influenza

United States
Insight Therapeutics, LLC
Brown University; Case Western Reserve University; Seqirus

Completed

Adjuvanted Influenza Vaccination in U.S. Nursing Homes

Influenza | Influenza-like Illness

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of a Subunit Trivalent Nonadjuvated Influenza Study Vaccine in Adults Aged 18 Years and Above

Human Influenza

Belgium
National Institute of Allergy and Infectious Diseases...

Completed

Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women

Influenza

United States
McGill University Health Centre/Research Institute...
The Arthritis Society, Canada

Unknown

Standard Versus High Dose Inactivated Influenza Vaccine in RA (IV-RA)

Rheumatoid Arthritis

Canada
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Investigate Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine(CAIV-T)in Healthy Adults Aged 18 to 59 and Healthy Adults Aged 60 Years and Older

Influenza

United States
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma

Asthma

Belgium
Emory University

Completed

Systems Biology of Trivalent Influenza Vaccine (TIV) in Young and Elderly

Influenza

United States
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
PATH
Centers for Disease Control and Prevention; Institut de Recherche pour le Developpement

Completed

Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical Africa

Influenza

Senegal
National Institute of Allergy and Infectious Diseases...
The Emmes Company, LLC

Completed

Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents

Influenza

United States
M.D. Anderson Cancer Center

Withdrawn

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
University of Rochester
National Institutes of Health (NIH); Dartmouth-Hitchcock Medical Center

Completed

Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children

Influenza

United States
GlaxoSmithKline

Completed

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

Influenza

United States, Canada
Novavax

Completed

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

Influenza

United States
Novartis Vaccines

Completed

Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age

Influenza Disease

Argentina, Australia, Chile, Philippines, South Africa
BiondVax Pharmaceuticals ltd.

Completed

Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (BVX006)

Influenza

Israel
University of Maryland, Baltimore
D'Antonio Consultants International, Inc.

Completed

Safety Study of Seasonal Influenza Vaccine by Jet Injection

Healthy Adults

United States
PharmaJet, Inc.

Completed

Jet Injection for Influenza (JIFI)

Influenza, Human

United States
British Columbia Centre for Disease Control

Unknown

TIV Infant/Toddler Response Evaluation - Follow-up for Influenza B Boost (TITRE IIB)

Influenza

Canada
US Department of Veterans Affairs
St. Louis University

Withdrawn

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly (CCTA #0005)

Aged | Influenza Vaccines

United States
Mark Prausnitz
Emory University

Completed

Inactivated Influenza Vaccine Delivered by Microneedle Patch or by Hypodermic Needle

Influenza

United States
Novavax
Department of Health and Human Services

Completed

Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young Adults

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US

Influenza

United States

3

Subscribe